Disclosures

Activity Directors
This activity has been planned and implemented under the sole supervision of the Course Directors, Jared Weiss, MD; Joshua Zeidner, MD; and Kaitlin Morrison, PhD, of the UNC School of Medicine, and the planning committee in association with the UNC Office of Continuing Professional Development (CPD). Dr. Weiss is a stockholder in Vesselon, Nuvalent, En Fuego Therapeutics, Vertex, Merus, Revmed; receives consulting fees from AZ, EMD Serono, Nanobiotix, PDS, Amgen, Pharmacosmos, GSK; and receives research grants from Pharmacosmos, Loxo, PDS, Genmab, Iovance, Nurix, TSCAN, Janus, BMS, Summit. Dr. Zeidner receives consulting fees from AbbVie, Ascentage, AstraZeneca, Aveo Pharmaceuticals, Crossbow Therapeutics, Cullinan, Foghorn, Genmab, Halia Therapeutics, Ipsen, Jazz, Johnson and & Johnson, Kura Oncology, Neogenomics, Novartis, Relmada Therapeutics, Rigel, Sellas Life Sciences, Servier, Shattuck Labs, Sumitomo Pharma, and Syndax; receives research grants from Akesobio, Aptevo Therapeutics, Arog, Ascentage, AstraZeneca, Auron Therapeutics, Daiichi Sankyo, Faron, Jazz, Kura Oncology, Lin Biosciences, Novartis, Sellas Life Sciences, Shattuck Labs, Stemline, Sumitomo Pharma, and Zentalis; serves on advisory boards for Astellas, Daiichi Sankyo, Genentech, Geron, Servier, Shattuck Labs, and Syndax; and is on safety review committees for Crossbow Therapeutics, and Foghorn. These financial relationships have been mitigated. Dr. Kaitlin Morrison has no relevant financial relationships with ineligible companies as defined by the ACCME. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.

ABIM MOC Part 2 Credit
The presenter receives a research grant from Regeneron. The presenter received a research grant from Daiichi Sankyo (ended 2025) and consuting fees from Acrotech Biopharma (ended 2025).

ACCME
The presenter receives a research grant from Regeneron. The presenter received a research grant from Daiichi Sankyo (ended 2025) and consuting fees from Acrotech Biopharma (ended 2025).

Accreditation Statements

1.00 ABIM MOC Part 2 Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Part 2 credit.

1.00 AMA PRA Category 1™ Credit
The School of Medicine of The University of North Carolina at Chapel Hill designates this activity for a maximum of 1.0 AMA PRA Category 1™ Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The School of Medicine of the University of North Carolina at Chapel Hill designates this live internet activity for a maximum of 1.0 AMA PRA Category 1™ Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Notice

In most cases, regulations prohibit the repeated use of the same educational activity (Live Webinar or Self-Paced, Online Course but not both) as it relates to satisfying CE requirements to maintain licensure. Attendees are also required to view a minimum of 53 minutes of the live webinar video to receive CE credit. Please contact your individual accreditation agencies for more details.

Altering or submitting modified certificates constitutes fraud that can result in punitive action by the accrediting agency.